Clinical trials
Clinically Significant Prostate Cancer clinical trials
Below are recruiting clinically significant prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 311 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05720130RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer found on PSMA scans
This trial tests [212Pb]Pb-ADVC001, a radiotherapy-like cancer treatment, in people with advanced prostate cancer that shows up on a special PSMA scan. It aims to find the safest dose and see whether it helps shrink or control metastatic cancer.
Brisbane, QueenslandAges 18 years+ - NCT05570994Enrolling by invitationPhase 1/Phase 2
PSMA-targeted radioactive drug for advanced prostate cancer
This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.
Vancouver, British ColumbiaAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Birmingham, AlabamaAges 18–100 - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Los Angeles, CaliforniaAges 18 years+ - NCT05454488RecruitingPhase 2
Study focal freezing for intermediate-risk prostate cancer
This trial tests whether freezing only the cancer area in the prostate (focal cryotherapy) can control intermediate-risk prostate cancer. It aims to limit treatment to one tumor focus while closely checking results with targeted and follow-up testing.
Houston, TexasAges 18 years+ - NCT05413850RecruitingPhase 1/Phase 2
Lu-177 PSMA drug study for advanced prostate cancer
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Miami, FloridaAges 18 years+ - NCT05346848RecruitingPhase 2
Darolutamide plus radiation for intermediate-risk prostate cancer
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
AvignonAges 18 years+ - NCT05036226RecruitingPhase 1/Phase 2
COAST therapy for advanced prostate or other solid tumors
This early-phase trial tests the COAST therapy approach in people with advanced solid tumor cancers or advanced prostate cancer that has continued to grow despite standard treatments. The study aims to see how well the treatment works and whether it is safe enough to continue studying.
Charleston, South CarolinaAges 18 years+ - NCT04947254RecruitingPhase 2
Add niraparib to hormone therapy after prostate radiation
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
Houston, TexasAges 18 years+ - NCT04812366RecruitingPhase 2
Genetic test-guided treatment before prostate surgery
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
Sacramento, CaliforniaAges 18 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Tucson, ArizonaAges 18 years+ - NCT03237702Recruiting
Study uses urine tests to understand prostate cancer
This study collects a small urine sample around the time of a prostate biopsy to look for chemical “signals” that may explain dangerous prostate cancer behavior. Your results are not shared with you, but the information may help researchers improve understanding and future care.
TaipeiAges 30–100 - NCT03880422Recruiting
Exercise and nutrition for weight and frailty after prostate cancer treatment
This study tests whether a structured exercise and nutrition program can improve obesity-related frailty and overall function in people with advanced prostate cancer who are taking hormone therapy (ADT). It may help with strength, mobility, and healthier body weight during/after ADT.
Buffalo, New YorkAges 18 years+ - NCT03819101RecruitingPhase 3
Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
OlomoucAges 18 years+ - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03650595Recruiting
MRI-guided laser treatment for prostate cancer
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
Toronto, OntarioAges 40–80 - NCT03423303Enrolling by invitation
Screening test to find early prostate cancer sooner
This trial checks whether an early prostate cancer screening approach can detect clinically significant prostate cancer sooner. It may help participants catch the disease at an earlier stage when treatment can be more effective.
HelsinkiAges 50–63 - NCT02526368RecruitingEarly Phase 1
Scan your prostate with special MRI using pyruvate to find high-grade cancer
This trial tests whether a specialized MRI scan using a pyruvate tracer can better detect high-grade (more aggressive) prostate cancer. It may help doctors find cancer more accurately and guide treatment decisions or targeted follow-up.
San Francisco, CaliforniaAges 18 years+ - NCT07657806RecruitingPhase 1
Study of DEC003M for advanced prostate cancer
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07580196Recruiting
Comparing lymph node removal approaches in aggressive prostate cancer
This trial compares two surgical approaches for removing lymph nodes during prostate cancer surgery in men with high-risk disease on one side of the prostate. The goal is to determine whether removing lymph nodes from both sides or just one side provides better outcomes.
Rozzano, MilanoAges 18 years+ - NCT07198633RecruitingPhase 1/Phase 2
Study of new drugs for advanced prostate cancer
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07135271Recruiting
Decision Support Tool for Newly Diagnosed Localised Prostate Cancer
This trial is testing a new decision support tool (BeSpoke) to help men with newly diagnosed localised prostate cancer make informed choices about their treatment. If you are deciding between two or more standard treatments, this tool may help you and your doctor pick the best one for you.
LondonAges Any age - NCT07072728RecruitingPhase 2
Psilocybin therapy for anxiety in cancer patients
This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.
Abbotsford, VictoriaAges 18–80
Hear when a new Clinically Significant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinically significant prostate cancer?
- Yes. Clin2 currently lists 311 recruiting clinically significant prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinically significant prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinically significant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.